Munck Thomasen (nepalprint0)

Evaluate long-term real-world treatment patterns and associated effectiveness and safety outcomes in patients with diabetic macular edema (DME) treated ≥36 months with 0.5mg ranibizumab. Open-label observational effectiveness study in 9 Belgian clinics. Included were primary treated eyes of 55 DME patients between August 2014 and March 2015 and followed for 3.5±1.8 years. Eyes were 21.8% treatment (TX)-naïve, 9.1% non-naïve with exclusive prior anti-VEGF treatment (PRIOR-anti-VEGF), and 63.6% non-naïve with other prior treatments (PRIOR-other). Intravitreal injections with ranibizumab were administered per ophthalmologists' best clinical judgment. Trend testing of changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) over time occurred using mixed regression analysis. The mean±SD number of treatments in the first year was 5.1±3.0 (TX-naïve), 4.5±2.7 (PRIOR-anti-VEGF) and 5.6±3.1 (PRIOR-other). At 12 months, BCVA increased by 8.9±16.4 letters from 59.7±9.3 at baseline in TX-nis an effective and safe long-term treatment for DME under conditions of significant heterogeneity in patients and treatment patterns. This real-world study confirms the effectiveness of ranibizumab in preventing a decline in BCVA and demonstrated initial improvement and subsequent retention of BCVA in DME patients ≥36 months. Ranibizumab initially reduced and then maintained CRT. However, these data reveal that treatment intensity and BCVA and CRT outcomes are lower than those found in early efficacy trials. Under-treatment likely accounts for this efficacy-effectiveness gap. Yet, intravitreal ranibizumab is an effective and safe long-term treatment for DME under conditions of significant heterogeneity in patients and treatment patterns. We conducted this trial to investigate a new wearable laser-eyewear (LEW). Images of an integrated camera are projected to the retina by a RGB-Laser (<1µW) and MEMS-mirror system. This enables a full-color live video as augmented reality embedded in the field of vision of the wearer. Thin parallel laser beams are projected following the principle of Maxwellian view through the center of the ocular lens to ensure independency of refractive errors. We performed a study with healthy subjects to test this independency. LEW was tested in 20 healthy subjects (aged between 21 and 60 years) with hyperopia, myopia, astigmatism and/or presbyopia. Subjects underwent standardized visual acuity (VA) measurements (ETDRS) without any correction, with LEW and with best correction. We found no significant correlation between refraction and VA while using LEW in linear regression (r=0.17). Still, younger participants performed better in terms of VA with the device compared to older participants despite no differences ities with less scattering. Low power mode (LPM) can be used for subthreshold retinal laser treatment by simply adjusting the laser parameters. Herein, we report the use of a modified LPM laser treatment for four cases of central serous chorioretinopathy (CSCR). We retrospectively reviewed the medical records of four patients (four eyes) with persistent CSCR who underwent modified LPM laser for leakage. The laser power was first titrated with a barely visible burn, and then treatment was applied using 33% laser energy by manually adjusting the laser power and duration. Serous retinal detachment completely resolved in all cases by 2 months after treatment. Autofluorescence images did not show any specific changes induced by laser burns. A modified LPM laser may provide a feasible treatment for persistent CSCR. A modified LPM laser may provide a feasible treatment for persistent CSCR.Thymomas are relatively slow growing with late presentation. Because of rarity and underreporting in India, there is an unmet need for evaluating the patient characteristics and assessing the factors affecting su